NEUE ADHOC VON IMNR!!!!!! - 500 Beiträge pro Seite

[Schnelle]

Wieder ne ganz nette adhoc! Das Baby wird heute ganz nett laufen!
Wednesday March 8, 7:02 am Eastern Time

Company Press Release

SOURCE: The Immune Response Corporation

The Immune Response Corporation and Cedars-Sinai
Medical Center Initiate Enrollment for a Phase I Trial of a Potential New
Vaccine Designed to Prevent The Recurrence of Brain Tumors

CARLSBAD, Calif., March 8 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today
announced that the Company and Cedars-Sinai Medical Center`s Maxine Dunitz Neurosurgical Institute have initiated
enrollment for a phase I trial of a potential new tumor vaccine designed to induce the patient`s immune system to recognize and
destroy tumor cells, thereby preventing or delaying the recurrence of malignant brain tumors (glioblastoma multiforme and
anaplastic astrocytoma). Dr. Keith Black, a world-renowned neurosurgeon and researcher, is the principal investigator of the
trial to be conducted at Cedars-Sinai Medical Center in Los Angeles, one of the largest and most respected non-profit
hospitals in the western United States.

``The development of cancer vaccines would be a major milestone toward the goal of targeting specific tumors with specific
treatments and offering patients the potential for a cure without many of the unpleasant side effects associated with conventional
treatment,`` said Dr. Black. ``Rather than bombarding the patient with chemicals and radiation, we`re devising strategies that
interfere with the cancer cells` very existence. This vaccine approach is part of a new generation of potential therapies based on
the latest biologic information about how brain tumors survive and what allows them to grow.``

According to Dr. Black, this study offers new hope for treating a type of cancer that has been particularly challenging and
frustrating to physicians and neurosurgeons in that gliomas (tumors that arise from supportive ``glial`` tissue of the brain) tend to
grow quickly, invade surrounding tissue, and recur frequently. Even aggressive therapies are not a cure, he said.

``We have been looking forward to this trial of a potential vaccine for the treatment of brain cancer patients who are afflicted by
one of the most aggressive and deadly forms of cancer known. We have the unique opportunity in this trial to treat patients after
their malignant tumor has been surgically removed, but before the cancer recurs,`` said Dr. Dennis J. Carlo, President and Chief
Executive Officer of The Immune Response Corporation. ``We are proud to be working with Dr. Keith Black and his group at
Cedars-Sinai, one of the leaders in the treatment of brain cancers. We have seen promising results from colon cancer trials
using similar vaccine technology in which the vaccine treatment appeared to stimulate immune responses specifically against the
patient`s colon cancer. The ability to harness the immune system to attack glioma would be a major step forward in the fight
against brain cancer.``

Methodology

The study is designed to enroll 12 patients who have just completed surgical resection and radiation treatment, currently the
standard of care for newly diagnosed glioma patients. The trial will investigate the Company`s platform vaccine technology that
utilizes a fibroblast (skin) cell line genetically modified to secrete cytokines (proteins that help orchestrate immune responses)
mixed with irradiated brain tumor (glioma) cell lines to seek to boost the immune system`s ability to recognize and destroy tumor
cells. The tumor cells and fibroblasts are derived from established cell lines grown in the laboratory. The patients will be
administered the vaccine intradermally (under the skin) 4 times (0, 2, 4 and 8 weeks) and will then be monitored for an
additional 8 weeks. The three goals of the study are to (a) evaluate the safety of multiple injections of this cell-line based
vaccine, (b) monitor the level of cellular and humoral (antibody) immune responses induced by the vaccine against the tumor,
and (c) examine the effects of immunizations on clinical progression of the disease. The trial is expected to be completed within
1 year.

GM-CSF

The cytokine genetically engineered into the fibroblast for this study is granulocyte-macrophage colony-stimulating factor
(GM-CSF), which has been effective in treating tumors of the central nervous system in animal models. GM-CSF enhances the
ability of the immune system to recognize molecules called antigens found on the surface of the tumor cells contained in the
vaccine. The immune system can only recognize these tumor-associated antigens when they are bound to specialized cells
called ``antigen presenters.`` GM-CSF most likely stimulates the immune system by augmenting the interaction between
tumor-associated antigens found in the vaccine and professional antigen presenting cells, notably dendritic cells at the site of
injection. Potential vaccines utilizing cancer cells and GM-CSF have shown promising effects in preclinical models, which the
Company believes supports the initiation of this clinical trial.

Glioma

Each year, about 15,000 cases of high-grade gliomas are diagnosed in the United States, with the numbers increasing yearly in
both adults and children. Prognosis for these patients is very poor. Surgical resections followed by either radiation or
chemotherapy have done little to alter the fatality of this cancer. The mean life expectancy of patients with glioblastoma
multiforme is only one year after its initial diagnosis and is only several months following recurrence. The Company believes that
novel immunotherapeutic-based treatments could fill a need in treating these cancers.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based
therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the
Company is working on several projects in gene therapy using proprietary delivery technology.

Cedars-Sinai Medical Center is one of the largest and finest nonprofit hospitals in the Western United States, renowned for its
diagnostic and treatment capabilities and its broad spectrum of clinical programs and services as well as for leading-edge
biomedical research and superlative medical education. Ranked among the 12 non-university hospitals in the nation for
research, the Medical Center has contributed such scientific advances as the excimer laser for clearing clogged arteries and the
Swan-Ganz catheter for monitoring the condition of cardiac patients at bedside, which have changed the practice of medicine
worldwide.

NOTE: News releases are also available through PR Newswire Company News On-Call fax service. For a menu of available
news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804,
extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet
Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a
variety of risk factors, including, but not limited to, whether this clinical trial or any additional clinical trials will be successfully
concluded. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not
limited to its report on Form 10-K for the year ended December 31, 1998 and subsequent Forms 10-Q. The Company
undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: The Immune Response Corporation

[Mr.Fresh]

Hut ab Schnelle, du bist wirklich schnelle!

[Thierri]

Dem Kurs hats nicht besonders gut getan. Schlußkurs 15,20E!!! Das reicht mir!!!!

[Mr.Fresh]

Hey Schnelle,
meinst Du diese Meldung aus dem Yahoo-Board?
Do I hear O-W-E-E,O-W-E-E,Ouch???
Hört sich eher nach Verzweiflung an. Bin mit IMNR inzwischen bei -28% angekommen. Werde noch etwas ausharren. So ist das, was nicht empfohlen wird, kennt auch keiner. Vielleicht werde ich doch lieber Lemming und kaufe ILEX, Medarex, Rhein Bio und Morphosys.

[Schnelle]

Gab anscheinend eine positives Research von IBD(weiß selbst noch nicht so ganz genau, was das ist), sieht aber nach einem Investmenthaus oder Zeitschrift a la Aktionär aus). Das yahoo-board ist auf jeden Fall mega bullish: Warten wir mal ab, was heute passiert.

Grüße, Schnelle

[Sgt.Highway]

Kann mir einer sagen warum immune response abstürzt?
Das Clinton-Gerede kann wohl kaum allein daran schuld sein, oder?
Bin bei IR selbst mit 32% in den Miesen. Was ist das für eine Empfehlung? weitere Frage: Ist der Boden schon in Sicht?

Anm.: Beobachte seid drei Monaten Interferon. unglaublich!!?!!

[Mr.Fresh]

Erstmal dank an Schnelle für die Antwort.
Doch, u.a. ist das Clinton-Gerede schuld! Erstmal wurden ALLE Biotechs niedergemacht um dann bei EINIGEN hervorzuheben, daß hier keine Gewinneinbußen durch das Abkommen eintreten werden. Dann kommt noch hinzu, daß Werte, über die derzeit viel geredet wird den Fokus auf sich ziehen und das Anlegergeld -gerade auch in Amiland- von Nachbarwerten ohne Ad hoc Feuerwerk abzapfen.
Nochmal zu dem "Bullish" im Yahoo-Board --- In welchem Board, zu welchem Wert sind die Schreiber nicht Bullish?
Wer "Bärig" ist, ist draußen und in einem anderen Board Bullish.
Gruß
Einer von den Zähen!